The effects of hormonotherapy administered concurrent radiotherapy and trastuzumab on cardiac toxicity in rats

被引:6
|
作者
Cihan, Yasemin Benderli [1 ]
Arsav, Vedat [2 ]
机构
[1] Kayseri Educ & Res Hosp, Clin Radiat Oncol, Kayseri, Turkey
[2] Kayseri Educ & Res Hosp, Clin Pathol, Kayseri, Turkey
来源
ANATOLIAN JOURNAL OF CARDIOLOGY | 2014年 / 14卷 / 04期
关键词
heart; fibrosis; radiotherapy; trastuzumab; hormonotherapy; cardiac toxicity; rat; BREAST-CANCER; POSTMENOPAUSAL WOMEN; RANDOMIZED-TRIAL; TAMOXIFEN; THERAPY; MORTALITY; RISK;
D O I
10.5152/akd.2014.4736
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: This experimental study aims to investigate whether radiotherapy (RT) plus trastuzumab (T) followed by subsequent hormonotherapy increase the cumulative toxic effect on cardiac functions in rats. Methods: A total of 70 Wistar Albino female rats with a mean weight 213 +/- 27 g were randomly divided into equal seven groups. The first group (C) underwent no procedure. The second group (RT) underwent the whole thoracic radiation including heart. The third group (T) was administered T through tail vein alone. The fourth group (RT+T+Tx) was administered T initially and the whole thoracic radiation at two hours, followed by tamoxifen at one week. The fifth group (RT+T+Le) was administered T and then underwent thoracic radiation, followed by letrozole. The sixth group (T+RT+An) was administered T and then underwent thoracic radiation, followed by anastrazole. The seventh group (T+RT+Ex) was administered T and then underwent thoracic radiation, followed by exemestane at one week. Hormonotherapy was administered to the rats in the Group 5, 6 and 7, as indicated in the Group 4. Radiation therapy was administered following T treatment at two hours as a single 12 Gy fraction. After the rats were sedated under anesthesia and sacrificed at 24 weeks, cardiac tissues were removed. Serial sections obtained following paraffin blockage were stained and the ratio of myocardial fibrosis was assessed. According to statistical analyses by the one-way ANOVA test and Tukey HSD test, a significant difference between test components. Results: At the end of the study, no loss and adverse effects were seen in any group. There was a statistically significant difference among atrium, ventricle and aorta (p<0.001). The mean value of fibrosis scores increased in the rats which underwent RT. In the assessment of atrium, a significant difference was found between RT group and RT+T+An group and also T group and RT+T+Fe group (p<0.001). In the assessment of ventricule, a statistically significant difference was observed among RT, RT+T+An and RT+T+Ex. In the assessment of aorta, the scores of RT group was significantly higher than RT+T+An and RT+T+Ex. A statistically significant difference was observed among these groups (p<0.001). Conclusion: Our study results suggested that there was no significant additional cardiotoxicity of adjuvant hormonotherapy following concomitant RT and T treatment, compared to RT in terms of cardiac fibrosis.
引用
收藏
页码:328 / 333
页数:6
相关论文
共 50 条
  • [1] Effects of hormonotherapy administered after concurrent radiotherapy and Trastuzumab on pulmonary fibrosis
    Cihan, Benderli Y.
    Deniz, K.
    Mutlu, H.
    Kaplan, B.
    [J]. HIPPOKRATIA, 2013, 17 (03) : 228 - 232
  • [2] The use of concurrent hormonotherapy and radiotherapy does not deteriorate radiation-induced cardiac toxicity
    Yavas, C.
    Yavas, G.
    Toy, H.
    Ata, O.
    [J]. HUMAN & EXPERIMENTAL TOXICOLOGY, 2017, 36 (08) : 795 - 801
  • [3] Cutaneous and cardiac toxicity of concurrent trastuzumab and adjuvant breast radiotherapy: a single institution series
    Meattini, Icro
    Cecchini, Sara
    Muntoni, Cristina
    Scotti, Vieri
    Cardillo, Carla De Luca
    Mangoni, Monica
    Bonomo, Pierluigi
    Nori, Jacopo
    Casella, Donato
    Simoncini, Roberta
    Orzalesi, Lorenzo
    Bianchi, Simonetta
    Livi, Lorenzo
    [J]. MEDICAL ONCOLOGY, 2014, 31 (04)
  • [4] Cutaneous and cardiac toxicity of concurrent trastuzumab and adjuvant breast radiotherapy: a single institution series
    Icro Meattini
    Sara Cecchini
    Cristina Muntoni
    Vieri Scotti
    Carla De Luca Cardillo
    Monica Mangoni
    Pierluigi Bonomo
    Jacopo Nori
    Donato Casella
    Roberta Simoncini
    Lorenzo Orzalesi
    Simonetta Bianchi
    Lorenzo Livi
    [J]. Medical Oncology, 2014, 31
  • [5] Potential impact of cardiac dose-volume on acute cardiac toxicity following concurrent trastuzumab and radiotherapy
    Cao, L.
    Hu, W. G.
    Kirova, Y. M.
    Yang, Z. Z.
    Cai, G.
    Yu, X. L.
    Ma, J. L.
    Guo, X. M.
    Shao, Z. M.
    Chen, J. Y.
    [J]. CANCER RADIOTHERAPIE, 2014, 18 (02): : 119 - 124
  • [6] Prospective monocentric study of the toxicity and the efficacy of concurrent trastuzumab to radiotherapy
    Jacob, J.
    Belin, L.
    Gobillion, A.
    Daveau-Bergerault, C.
    Dendale, R.
    Beuzeboc, P.
    Campana, F.
    Bollet, M. -A.
    Fourquet, A.
    Kirova, Y. M.
    [J]. CANCER RADIOTHERAPIE, 2013, 17 (03): : 183 - 190
  • [7] Concurrent Trastuzumab and Breast Radiotherapy in the Adjuvant Setting: Analysis of Acute Toxicity
    Anderson, P. R.
    Freedman, G.
    Li, T.
    Nicolaou, N.
    Denlinger, C.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S202 - S203
  • [8] Early cardiac toxicity following adjuvant radiotherapy of left-sided breast cancer with or without concurrent trastuzumab
    Cao, Lu
    Cai, Gang
    Chang, Cai
    Yang, Zhao-Zhi
    Feng, Yan
    Yu, Xiao-Li
    Ma, Jin-Li
    Wu, Jiong
    Guo, Xiao-Mao
    Chen, Jia-Yi
    [J]. ONCOTARGET, 2016, 7 (01) : 1042 - 1054
  • [9] The Effects of Hormonotherapy Following Concomitant Use of Trastuzumab and Radiation Therapy on Late Skin Toxicity
    Cihan, Yasemin B.
    Arsav, Vedat
    [J]. UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2014, 24 (03): : 163 - 170
  • [10] Impact on Cardiac Toxicity With Trastuzumab and Radiotherapy: The Question Is Still Ongoing
    Magne, Nicolas
    Vedrine, Lionel
    Chargari, Cyrus
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) : E239 - E239